Catalyst Dossier · compiled by CeliA 🧫

Swedish Orphan Biovitrum AB (SOBI.ST)

Biotechnology · market cap $14.6B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-05 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Swedish Orphan Biovitrum AB (SOBI.ST) is a Stockholm-listed rare-disease and specialty biotech with approximately 1,890 employees and a market cap of ~$14.6B. The company operates a broad late-stage pipeline spanning rare hematology, immunology, metabolic, and orphan diseases, with several Phase 3 readouts expected in H2 2026 and early 2027. Analyst price targets range from 350 to 550 (mean ~474), implying meaningful upside or downside depending on catalyst execution.

The catalyst path

2026-10-05 (est.)Phase 3 · Physician's Choice medicationsimp 9/10
2026-12-30 (est.)Phase 2 · Pacritinibimp 7/10
2026-12-31 (est.)Phase 3 · Pacritinibimp 9/10
2027-03-15 (est.)Phase 3 · Efanesoctocog alfaimp 9/10

Pipeline

Asset	Phase	Indication
SEL-212 high-dose	Phase 3	Chronic Gout
SEL-212 low-dose	Phase 3	Chronic Gout
SOBI003	Phase 2	Sanfilippo Syndrome Type A (MPS IIIA)
Cyclophosphamide	Phase 3	Cancer
NI-0501	Phase 3	Primary Haemophagocytic Lymphohistiocytosis
Efanesoctocog alfa	Phase 3	Hemophilia A, Severe
Anakinra	Phase 3	Still's Disease, Juvenile Onset
Physician's Choice medications	Phase 3	Primary Myelofibrosis
rhBSSL	Phase 2	Replacement Therapy in Preterm Infants
Pacritinib	Phase 3	VEXAS
Paclitaxel	Phase 2	Dysphagia
Nitisinone	Phase 3	Hereditary Tyrosinemia, Type I
Methotrexate	Phase 2	Graft Versus Host Disease
BVT.115959	Phase 2	Diabetic Neuropathic Pain
Anakinra 100 mg	Phase 2	Acute Gouty Arthritis
palifermin	Phase 3	Mucositis
cisplatin chemotherapy	Phase 3	Mucositis
Pegcetacoplan	Phase 3	Transplant-Associated Thrombotic Microangiopathy
Palifermin before only	Phase 3	Multiple Myeloma
Emapalumab	Phase 3	Macrophage Activation Syndrome

Price & technical context

3-month

+17.8%

6-month

+16.8%

12-month

+4.3%

52-wk range

$246.60–$343.60

vs 50-day MA

+0.8%

vs 200-day MA

+11.3%

Realized vol

29.5%

Max drawdown

-28.8%

Daily closes through 2025-12-12. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SOBI.ST (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.